Last post by dmorfey says : Don't waste the hard work of others.. Shorts and other manipulators are giving you a perfect opportunity to buy some really cheap shares and/or average down by increasing your investment.
True today as well!
bearofbleecker, do you see any good buys in this market? I have a decent position in MDVN and was thinking of adding more. Would appreciate your thoughts on MDVN and other potential good buys. Thanks
as far as this thread is concerned...bearofbleecker has made the most sensible comment...
BTW, from one of your May posts, I gather you have ITMN, INCY, and PCYC as well. Do you see potential in RNAi stocks such as ALNY? Some of the recents biotech with recent IPOs are beaten down but unable to assess relative quality/potential.
Sorry that's not me. I rarely write on msgboards but do shadow good/great biotech investors such as yourself :) I was former dubble_bee and somewhat active on ONXX msgboard (bought in the 20's). Thanks.
John, Will appreciate if you can share the other biotechs that interest you. Your ONXX board msgs were very informative. I am long GILD and MDVN. Any others that you think have a good risk/reward ratio at present?
Hello, am from the ONXX board and used to follow you for your thoughtful comments. Would appreciated if you could share current biotech picks and what you think have the most opportunity on risk/reward basis. Thanks! I hold GILD and MDVN.
I will be happy if offer is much higher than $150. But realistically, I think ONXX and AMGN are very close to sealing the deal and this was the last item that will do it. I think ONXX and AMGN deal happens very soon. AZN is still doing due diligence but I doubt ONXX will wait for a bid to come from them given the leak that both ONXX and AMGN are OK with $130.
ONXX should show finger to AMGN for wasting valuable time
ONXX should focus on its business rather than on AMGN people. Let the game and dance end.
Unclear to me as well - do they want access to data before signing the agreement or after signing but before the closure of deal (2 to 3 months). Likely they want agreement to say that AMGN will get data before closure completion. ONXX probably does not want to add that to agreement because AMGN may use that as a reason to back out without/mitigated monetory repercussions to them. I think they have haggling over the fine print of the agreement. I think in the end a deal will be done at 130$ or higher. This leak may also be related to options expiration so people who are ready to take a additional risk may be able to make some money here IMO.
If Bayer is getting into the picture, IMO, it might be to buy out the Nexavar and Stivarga pieces. AMGN is probably more interested in Kyprolis and opro and less for other pieces. But not sure the impact if any of Bayer showing interest this late.